Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics
Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).
- Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).
- Function is leveraging its CRISPR-enabled platform to understand disease in unprecedented and patient-specific detail.
- By moving beyond traditional gene sequencing to measuring gene function, the Volastra and Function teams aim to identify which patients would benefit from treatment with Volastra’s KIF18A inhibitors.
- CRISPR technology has transformed precision medicine, and we are excited by the potential of Function’s innovative platform to expand the pool of patients that will benefit from KIF18A inhibitors.”